First test: can a new drug boost the power of standard cancer treatment?
NCT ID NCT02402920
Summary
This early-stage study tested a new drug called pembrolizumab (MK-3475) when given alongside standard chemotherapy and radiation for small cell lung cancer. The main goal was to find a safe dose and understand the side effects of this combination. Researchers also wanted to see if adding this immunotherapy drug could help patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.